Viatris is First to Receive FDA Approval of Generic Restasis® (Cyclosporine Ophthalmic Emulsion 0.05%) to Treat Dry Eye Disease
PITTSBURGH, Feb. 3, 2023 /PRNewswire/ — Viatris Inc. (NASDAQ: VTRS) today announced that its subsidiary, Mylan Pharmaceuticals Inc., has received approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Cyclosporine Ophthalmic Emulsion 0.05%,…